[Basic and clinical evaluation of an immunoradiometric competitive inhibition assay for sialyl TN antigen: (2). Evaluation of clinical significance. STN Study Group]. 1989

H Imura, and T Mori, and H Ohkura, and M Ishii, and H Ariyoshi, and J Endo, and M Kitao, and I Takeda, and H Kobayashi, and M Inoue

The clinical significance of serum sialyl Tn antigen as a tumor marker was evaluated using "STN Otsuka" kits. Results indicated that the antigen was frequently elevated in sera from patients with ovarian cancers (43.1%, 140/325), including serous cystadenocarcinoma (51.6%, 63/122), mucinous cystadenocarcinoma (55.6%, 30/54), endometrioid carcinoma (56.5%, 13/23), and mesonephroid carcinoma (40.0%, 6/15). The positive frequency of sialyl Tn antigen in patients with ovarian carcinoma was less than the frequency of CA 125 (75.5%, 194/257) or sialyl SSEA-1 (47.2% 83/176). However, the false positive rate of sialyl Tn antigen in patients with benign gynecological disorders (3.7%, 15/401) was much lower than the false positive rates of other antigens; such as CA 125 (48.4%, 155/320) and sialyl SSEA-1 (19.2%, 51/266). The serum level of sialyl Tn antigen reflected the clinical activity of the disease quite well in patients with ovarian cancers. The sialyl Tn antigen was concluded to be a useful serum tumor marker for ovarian cancers.

UI MeSH Term Description Entries
D008649 Mesonephroma A rare tumor of the female genital tract, most often the ovary, formerly considered to be derived from mesonephric rests. Two varieties are recognized: (1) clear cell carcinoma, so called because of its histologic resemblance to renal cell carcinoma, and now considered to be of muellerian duct derivation and (2) an embryonal tumor (called also ENDODERMAL SINUS TUMOR and yolk sac tumor), occurring chiefly in children. The latter variety may also arise in the testis. (Dorland, 27th ed) Mesonephromas
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D011933 Reagent Kits, Diagnostic Commercially prepared reagent sets, with accessory devices, containing all of the major components and literature necessary to perform one or more designated diagnostic tests or procedures. They may be for laboratory or personal use. Diagnostic Reagent Kits,Diagnostic Reagents and Test Kits,Diagnostic Test Kits,In Vitro Diagnostic Device,In Vitro Diagnostic Devices,In Vitro Diagnostic Medical Device,In Vitro Diagnostic Medical Devices,Kits, Diagnostic Reagent,Diagnostic Reagent Kit,Diagnostic Test Kit,Kit, Diagnostic Reagent,Kit, Diagnostic Test,Kits, Diagnostic Test,Reagent Kit, Diagnostic,Test Kit, Diagnostic,Test Kits, Diagnostic
D002272 Carcinoembryonic Antigen A glycoprotein that is secreted into the luminal surface of the epithelia in the gastrointestinal tract. It is found in the feces and pancreaticobiliary secretions and is used to monitor the response to colon cancer treatment. Antigens, CD66e,CD66e Antigen,Antigen, CD66e,Antigen, Carcinoembryonic,CD66e Antigens
D003536 Cystadenocarcinoma A malignant neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. The neoplastic cells manifest varying degrees of anaplasia and invasiveness, and local extension and metastases occur. Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. (Stedman, 25th ed) Cystadenocarcinomas
D004715 Endometriosis A condition in which functional endometrial tissue is present outside the UTERUS. It is often confined to the PELVIS involving the OVARY, the ligaments, cul-de-sac, and the uterovesical peritoneum. Endometrioma,Endometriomas,Endometrioses
D005260 Female Females
D006017 Glycolipids Any compound containing one or more monosaccharide residues bound by a glycosidic linkage to a hydrophobic moiety such as an acylglycerol (see GLYCERIDES), a sphingoid, a ceramide (CERAMIDES) (N-acylsphingoid) or a prenyl phosphate. (From IUPAC's webpage) Glycolipid
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

H Imura, and T Mori, and H Ohkura, and M Ishii, and H Ariyoshi, and J Endo, and M Kitao, and I Takeda, and H Kobayashi, and M Inoue
June 1989, Gan to kagaku ryoho. Cancer & chemotherapy,
H Imura, and T Mori, and H Ohkura, and M Ishii, and H Ariyoshi, and J Endo, and M Kitao, and I Takeda, and H Kobayashi, and M Inoue
June 1989, Gan to kagaku ryoho. Cancer & chemotherapy,
H Imura, and T Mori, and H Ohkura, and M Ishii, and H Ariyoshi, and J Endo, and M Kitao, and I Takeda, and H Kobayashi, and M Inoue
July 2010, Nihon rinsho. Japanese journal of clinical medicine,
H Imura, and T Mori, and H Ohkura, and M Ishii, and H Ariyoshi, and J Endo, and M Kitao, and I Takeda, and H Kobayashi, and M Inoue
August 2005, Nihon rinsho. Japanese journal of clinical medicine,
H Imura, and T Mori, and H Ohkura, and M Ishii, and H Ariyoshi, and J Endo, and M Kitao, and I Takeda, and H Kobayashi, and M Inoue
July 1991, Gan to kagaku ryoho. Cancer & chemotherapy,
H Imura, and T Mori, and H Ohkura, and M Ishii, and H Ariyoshi, and J Endo, and M Kitao, and I Takeda, and H Kobayashi, and M Inoue
May 1992, Cancer,
H Imura, and T Mori, and H Ohkura, and M Ishii, and H Ariyoshi, and J Endo, and M Kitao, and I Takeda, and H Kobayashi, and M Inoue
May 1987, Gan to kagaku ryoho. Cancer & chemotherapy,
H Imura, and T Mori, and H Ohkura, and M Ishii, and H Ariyoshi, and J Endo, and M Kitao, and I Takeda, and H Kobayashi, and M Inoue
May 1987, Gan to kagaku ryoho. Cancer & chemotherapy,
H Imura, and T Mori, and H Ohkura, and M Ishii, and H Ariyoshi, and J Endo, and M Kitao, and I Takeda, and H Kobayashi, and M Inoue
November 1990, Nihon Sanka Fujinka Gakkai zasshi,
H Imura, and T Mori, and H Ohkura, and M Ishii, and H Ariyoshi, and J Endo, and M Kitao, and I Takeda, and H Kobayashi, and M Inoue
June 1996, Kaku igaku. The Japanese journal of nuclear medicine,
Copied contents to your clipboard!